STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the ...

STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the ...

Additional information, including the accepted abstracts, can be accessed on the EULAR 2025 Congress website. Presentation materials will be made available in the Science section under Scientific ...

today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in ...

Additional information, including the accepted abstracts, can be accessed on the EULAR 2025 Congress website. Presentation materials will be made available in the Science section under Scientific ...

SAN DIEGO - Fate Therapeutics Inc. (NASDAQ: FATE), a biopharmaceutical company currently valued at approximately $140 million, announced today that it will present clinical and preclinical data ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress.

EULAR, the European Alliance of Associations for Rheumatology holds its annual congress in Barcelona from June 11-14, 2025. The EULAR review committee and board have now accepted Shanton's ...

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced ...